Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma

Am J Hematol. 2012 Oct;87(10):E68-71. doi: 10.1002/ajh.23286. Epub 2012 Jul 27.
No abstract available

Publication types

  • Comparative Study
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal, Murine-Derived / administration & dosage
  • Antibodies, Monoclonal, Murine-Derived / adverse effects
  • Antibodies, Monoclonal, Murine-Derived / economics
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / economics
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor
  • Cost-Benefit Analysis
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • Cyclophosphamide / economics
  • Doxorubicin / administration & dosage
  • Doxorubicin / adverse effects
  • Doxorubicin / economics
  • Humans
  • Kaplan-Meier Estimate
  • Lymphoma, Follicular / drug therapy*
  • Lymphoma, Follicular / economics
  • Lymphoma, Follicular / genetics
  • Middle Aged
  • Polymerase Chain Reaction
  • Prednisone / administration & dosage
  • Prednisone / adverse effects
  • Prednisone / economics
  • Proportional Hazards Models
  • Remission Induction
  • Rituximab
  • Treatment Outcome
  • Vincristine / administration & dosage
  • Vincristine / adverse effects
  • Vincristine / economics
  • Young Adult

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Biomarkers, Tumor
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol